Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Invest New Drugs. 2010 Aug 10;30(1):258–265. doi: 10.1007/s10637-010-9504-5

Table 4.

Combination of Gemcitabine and Docetaxel

Study Phase Disease Gemcitabine dose (mg/ m2) Days 1,8 Docetaxel dose (mg/ m2) on Day 8 Cycle duration Commen
Matsui [38] I/II NSCLC 1000 mg/m2 50 mg/m2 21
Hensley [39] II Uterine Leiomyosarcoma 900 FDR mg/m2 100 mg/m2 21

  • Neutropenia 12% grade 4, 5% Grade 3

  • Anemia 24% grade 3

  • Thrombocytopenia grade 3 in 9.5%, grade 4 in 5%

  • GCSF administered
Georgoulilas [40] III NSCLC 1100 mg/m2 75 mg/m2 21
Ebeling [41] Retrosp STS 900 mg/m2 100 mg/m2 21

  • 47% grade 3 or 4 hematological toxicity

  • 26% grade 3 or 4 nonhematological toxicity
Boukovinas [42] II elderly NSCLC 1100 mg/m2 100 mg/m2 21

  • GCSF administered

  • Neutropenia 18.2% Grade 3–4

  • Febrile neutropenia in 3.9% patients
Labourey [43] II HNC 1000 mg/m2 75 mg/m2 21

  • Neutropenia Grade 3 or 4 in 45% (18 patients).

  • Three treatment-related deaths (7.5%) due to infection were reported.
Maki [44] II STS 900 mg/m2 FDR 100 mg/m2 21

  • GCSF administered